Stanmore appoints Eric Dodd CFO
This article was originally published in Clinica
UK orthopaedics firm Stanmore Implants has appointed Eric Dodd chief financial officer. Mr Dodd was most recently CFO of European biotech company Antisoma, a position he held for three years. Before this, he was group finance director for Morse, a British IT consultancy group. Mr Dodd has also worked for GlaxoSmithKline and Deloitte & Touche. Elstree-based Stanmore is currently expanding its product offering and entering new markets. In June, the company received US FDA 510(k) clearance for its Juvenile Tumour System (JTS), a noninvasive distal femoral replacement implant that uses an electromagnetic device to lengthen the prosthesis (www.clinica.co.uk, 27 June 2011).